Diabetes Self-Management Blog

New data from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study has shown that taking the drug fenofibrate (brand names TriCor, Lofibra, and others) may help people with Type 2 diabetes and symptoms of the metabolic syndrome reduce their risk of cardiovascular disease.

I wrote about a substudy of the FIELD study last year in the blog entry “Fibrate Drug Alone Doesn’t Cut Heart Risks for Type 2’s.” The data released at that time showed that five years of fenofibrate therapy alone did not decrease markers of cardiovascular disease in people with Type 2 diabetes any more than taking a placebo (inactive pill) did.

However, a new analysis, published in the March 2009 issues of Diabetes Care, looked at people with Type 2 diabetes and a cluster of factors that can raise people’s risk of heart disease (and diabetes for those who don’t already have it), such as abdominal obesity, high blood pressure, high fasting blood glucose, high triglycerides, and low HDL (or “good”) cholesterol. Typically, when a person has three or more of these conditions, he is considered to have metabolic syndrome).

The FIELD researchers examined their data to find out whether people who had symptoms of the metabolic syndrome would benefit more from taking fenofibrate than those who didn’t have the condition. They found that more than 80% of the study’s nearly 10,000 participants did have metabolic syndrome, and that those with metabolic syndrome had a higher risk of cardiovascular “events” (such as heart attack) than those without.

The researchers also found that certain groups of people who took fenofibrate over the five-year study period had significantly lower rates of cardiovascular events. Namely, people with high blood pressure and those with abnormal blood lipid (triglyceride and cholesterol) levels saw the greatest risk reduction from treatment with fenofibrate. The researchers also found that people who had no history of cardiovascular disease lowered their risk more than those who had already experienced a cardiovascular event.

You can read the study abstract here.

Another study of fenofibrate, which I also blogged about last year (in “Two Lipid Drugs May Be Better Than One”) found that combining fenofibrate with the statin drug simvastatin (Zocor) led to fewer markers for cardiovascular disease risk in people with Type 2 diabetes after 12 weeks.

The FIELD researchers concluded that treatment with fenofibrate is likely to be more useful in people with Type 2 diabetes who also have features of metabolic syndrome.


  1. Great idea, but will this work over the long run?

    Posted by Gabriel-Alfonso |

Post a Comment

Note: All comments are moderated and there may be a delay in the publication of your comment. Please be on-topic and appropriate. Do not disclose personal information. Be respectful of other posters. Only post information that is correct and true to your knowledge. When referencing information that is not based on personal experience, please provide links to your sources. All commenters are considered to be nonmedical professionals unless explicitly stated otherwise. Promotion of your own or someone else's business or competing site is not allowed: Sharing links to sites that are relevant to the topic at hand is permitted, but advertising is not. Once submitted, comments cannot be modified or deleted by their authors. Comments that don't follow the guidelines above may be deleted without warning. Such actions are at the sole discretion of DiabetesSelfManagement.com. Comments are moderated Monday through Friday by the editors of DiabetesSelfManagement.com. The moderators are employees of Madavor Media, LLC., and do not report any conflicts of interest. A privacy policy setting forth our policies regarding the collection, use, and disclosure of certain information relating to you and your use of this Web site can be found here. For more information, please read our Terms and Conditions.

Type 2 Diabetes
Metformin Study Currently Recruiting (08/19/14)
New Metformin Combo Drug Approved for Type 2 Diabetes (08/13/14)
FDA Approves New Oral Drug for Type 2 Diabetes (08/07/14)
Dispelling the Myths of Insulin Therapy (08/01/14)

Heart Health
Pistachios Offer Protection for People With Diabetes (08/29/14)
Which Butter (or Spread) Is Better? (07/28/14)
High-Salt Diet Doubles Heart Risk in Type 2 Diabetes (07/25/14)
One in Ten Heart Attack Patients Has Undiagnosed Diabetes (06/19/14)

Diabetes Research
Pistachios Offer Protection for People With Diabetes (08/29/14)
New Approach for Neuropathy Pain? (08/18/14)
Metformin Study Currently Recruiting (08/19/14)
FDA Approves New Oral Drug for Type 2 Diabetes (08/07/14)

Diabetes News
Pistachios Offer Protection for People With Diabetes (08/29/14)
New Approach for Neuropathy Pain? (08/18/14)
FDA Approves New Oral Drug for Type 2 Diabetes (08/07/14)
Shift Work Tied to Increased Type 2 Diabetes Risk (07/31/14)



Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.